Effect of rosuvastatin 20 mg versus rosuvastatin 5 mg plus ezetimibe on statin side-effects in elderly patients with atherosclerotic cardiovascular disease: Rationale and design of a randomized, controlled SaveSAMS trial
Study context
- Population
- Patients aged ≥70 years with established atherosclerotic cardiovascular disease (ASCVD)
- Planned comparison
- Rosuvastatin 20 mg vs rosuvastatin/ezetimibe 5/10 mg
- Primary endpoint
- Statin-associated muscle symptoms (SAMS), by treatment strategy
- Follow-up
- 6 months
Methodological detailsrationale and design, investigator-initiated, multicentre, 1:1 randomisation
- Rationale and design
- Investigator-initiated
- Multicentre
- 1:1 randomisation
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Effect of rosuvastatin 20 mg versus rosuvastatin 5 mg plus ezetimibe on statin side-effects in elderly patients with atherosclerotic cardiovascular disease: Rationale and design of a randomized, controlled SaveSAMS trial. Am Heart J. Published 17 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →